Novartis reaches a crossroads as drug sales dwindle
Article Abstract:
Novartis AG plans to unveil the latest data from clinical trials of several promising drugs that target disorders ranging from severe eye problems and diabetes to cancer and irritable bowel syndrome. If tests are successful and the new medicines make it to market, the pharmaceutical division will rebound strongly from slow sales growth over the past 18 months, analysts predict. The five new medicines poised for launch during the next two years could rack up combined annual sales of five billion Swiss francs by the year 2005. The drugs would double the drug division's revenue growth to 10% next year from an estimated 5% this year.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Drug firms battle for pre-eminence in marketing of multiple sclerosis drug
Article Abstract:
Biogen Inc. of the US, Ares-Serono SA of Switzerland and Schering AG of Germany's research advances are propelling a trans-Atlantic marketing competition among these drug companies over their virtually identical versions of beta interferon, which is the generic name for drug that treat multiple sclerosis. The competing beta interferon versions include Avonex for Biogen, Rebif for Area-Serono and Schering's Betaferon, which is sold in the US under the name Betaseron. Schering anticipates formal clearance for its Betaferon from the European Commission early in 1999 and broadened approval in the US during 1999.
Comment:
Its Betaferon, a beta interferon version, competes with Ares-Serono's Rebif and Biogen Inc's Avonex
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Roche withdraws Posicor, dimming sales prospects
Article Abstract:
Roche Holding Ltd. has voluntary removed Posicor off the market due to fears of serious drug interactions between the drug and some 30 extensively used drugs, ranging from cholesterol-reducing remedies to the new impotence drug Viagra. Posicor, new drug for treating high blood pressure, has been allowed to be sold commercially by regulators and is available in 38 countries. The move to withdraw Posicor has caused Roche's stock price to tumble and its prospect of accelerating slumping sales to dim.
Comment:
Voluntary removes Posicor off the mrkt due to fears of serious drug interactions with some 30 drugs in the market
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Nabisco revamps entire Primo line. Maple Leaf cooks up new marketing plan. Natrel relaunches its Ontario milk lines
- Abstracts: Company profiles: L'Oreal SA. Company profiles: Schwarzkopf & Henkel Cosmetics GmbH. Company profiles: Beiersdorf AG
- Abstracts: Company profiles: The Procter & Gamble Company. Textile washing products: company profiles: Procter & Gamble Company
- Abstracts: Prices & margins: typical retail prices. The Benelux market for textile washing products: emerging product sectors: new launches
- Abstracts: Key trends & developments: tourism receipts & expenditure. Market sectors: domestic: accommodation